Cargando…
Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone
Background. Mitoxantrone (MTX) and Rituximab (RTX) are successfully used for treatment of multiple sclerosis (MS) and can be combined to increase efficacy. Objective. We used MTX, RTX, and methylprednisolone in a single combined regiment and observed patients prospectively. Methods. We present resul...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784158/ https://www.ncbi.nlm.nih.gov/pubmed/24109519 http://dx.doi.org/10.1155/2013/748127 |
_version_ | 1782477527672946688 |
---|---|
author | Evdoshenko, Evgeniy Maslyanskiy, Alexey Lapin, Sergey Zaslavsky, Leonid Dobson, Ruth Totolian, Areg Skoromets, Alexander Bar-Or, Amit |
author_facet | Evdoshenko, Evgeniy Maslyanskiy, Alexey Lapin, Sergey Zaslavsky, Leonid Dobson, Ruth Totolian, Areg Skoromets, Alexander Bar-Or, Amit |
author_sort | Evdoshenko, Evgeniy |
collection | PubMed |
description | Background. Mitoxantrone (MTX) and Rituximab (RTX) are successfully used for treatment of multiple sclerosis (MS) and can be combined to increase efficacy. Objective. We used MTX, RTX, and methylprednisolone in a single combined regiment and observed patients prospectively. Methods. We present results of observational pilot study of combined therapy of RTX and MTX in 28 patients with active MS. Therapeutic protocol consisted of two infusions within 14 days. First infusion was 1000 mg methylprednisolone (MP) IV, 1000 mg RTX IV, and 20 mg MTX IV. On day 14, 1000 mg MP IV and 1000 mg RTX IV were given. Patients were followed prospectively from 12 to 48 months. Results and Conclusion. There were no relapses among all 28 patients during the observation period. B-cell depletion of CD19+ and CD19+/CD27+ memory B-cell subpopulation in both compartments was confirmed in all patients at 6 months. We found a more rapid reconstitution of B cells in the CSF than in the peripheral blood and longstanding depression of CD19+CD27+ memory B-cell. Conclusion. Effectiveness of combined regimen of RTX and MTX could be related to longstanding depletion of CD19+CD27+ memory B-cell subset. |
format | Online Article Text |
id | pubmed-3784158 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-37841582013-10-09 Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone Evdoshenko, Evgeniy Maslyanskiy, Alexey Lapin, Sergey Zaslavsky, Leonid Dobson, Ruth Totolian, Areg Skoromets, Alexander Bar-Or, Amit ISRN Neurol Clinical Study Background. Mitoxantrone (MTX) and Rituximab (RTX) are successfully used for treatment of multiple sclerosis (MS) and can be combined to increase efficacy. Objective. We used MTX, RTX, and methylprednisolone in a single combined regiment and observed patients prospectively. Methods. We present results of observational pilot study of combined therapy of RTX and MTX in 28 patients with active MS. Therapeutic protocol consisted of two infusions within 14 days. First infusion was 1000 mg methylprednisolone (MP) IV, 1000 mg RTX IV, and 20 mg MTX IV. On day 14, 1000 mg MP IV and 1000 mg RTX IV were given. Patients were followed prospectively from 12 to 48 months. Results and Conclusion. There were no relapses among all 28 patients during the observation period. B-cell depletion of CD19+ and CD19+/CD27+ memory B-cell subpopulation in both compartments was confirmed in all patients at 6 months. We found a more rapid reconstitution of B cells in the CSF than in the peripheral blood and longstanding depression of CD19+CD27+ memory B-cell. Conclusion. Effectiveness of combined regimen of RTX and MTX could be related to longstanding depletion of CD19+CD27+ memory B-cell subset. Hindawi Publishing Corporation 2013-09-10 /pmc/articles/PMC3784158/ /pubmed/24109519 http://dx.doi.org/10.1155/2013/748127 Text en Copyright © 2013 Evgeniy Evdoshenko et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Evdoshenko, Evgeniy Maslyanskiy, Alexey Lapin, Sergey Zaslavsky, Leonid Dobson, Ruth Totolian, Areg Skoromets, Alexander Bar-Or, Amit Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone |
title | Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone |
title_full | Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone |
title_fullStr | Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone |
title_full_unstemmed | Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone |
title_short | Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone |
title_sort | dynamics of b-cell populations in csf and blood in patients treated with a combination of rituximab and mitoxantrone |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784158/ https://www.ncbi.nlm.nih.gov/pubmed/24109519 http://dx.doi.org/10.1155/2013/748127 |
work_keys_str_mv | AT evdoshenkoevgeniy dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone AT maslyanskiyalexey dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone AT lapinsergey dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone AT zaslavskyleonid dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone AT dobsonruth dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone AT totolianareg dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone AT skorometsalexander dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone AT baroramit dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone |